Jim W Li

This inventor holds 38 USPTO granted patents and 10 published patent applications and 11 EPO patents, primarily in Biochemical Inhibitors. Top assignees: Calithera Biosciences, Inc., Roche Palo Alto LLC, Magnachip Semiconductor, Inc.. Active years: 2007-2025.

USPTO Granted Patents = 38 (Patent Applications = 10)

% Patents Active = 65.8

EPO Patents = 11 (Patent Applications = 25)

Average Co-Inventor Count = 3.7

ph-index = 9

Forward Citations = 246(Granted Patents)

Location History:

San Jose, CA (US) (2007 - 2013)
San Francisco, CA (US) (2011 - 2024)

Company Filing History:

14 out of 30

Calithera Biosciences, Inc.

Magnachip Semiconductor, Inc.

patents

4. 2 out of 25

Crosstek Capital, LLC

patents

5. 2 out of 641

Kla-Tencor Technologies Corporation

patents

6. 1 out of 1

Antengene Therapeutics Limited

patent

7. 1 out of 1

Antengent Therapeutics Limited

patent

8. 1 out of 196

Intellectual Ventures Ii LLC

patents

9. 1 out of 1

Precision Pharmaceuticals, Inc.

patent

10. 2 out of 834,307

Other

patents

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

Ectonucleotidase Inhibitors

Arginase Inhibitors

Glutaminase Inhibitors

Antiviral Compounds

HCV Polymerase Inhibitors

Pixel Crosstalk

CMOS Image Sensors

Intensity Distribution

Optical Apparatus

Row Noise Reduction

Color Filter Design

Alpha 1A/B Antagonists

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421273 - Ectonucleotidase inhibitors and methods of use thereof (2025-09-23),

2. 12054501 - Compositions and methods for inhibiting arginase activity (2024-08-06),

3. 11858957 - Ectonucleotidase inhibitors and methods of use thereof (2024-01-02),

4. 11208414 - Ectonucleotidase inhibitors and methods of use thereof (2021-12-28),

5. 11078228 - Ectonucleotidase inhibitors and methods of use thereof (2021-08-03),

6. 11034715 - Ectonucleotidase inhibitors and methods of use thereof (2021-06-15),

7. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

8. 10851118 - Compositions and methods for inhibiting arginase activity (2020-12-01),

9. 10844080 - Compositions and methods for inhibiting arginase activity (2020-11-24),

10. 10793535 - Heterocyclic glutaminase inhibitors (2020-10-06),

11. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

12. 10570167 - Ectonucleotidase inhibitors and methods of use thereof (2020-02-25),

13. 10472364 - Ectonucleotidase inhibitors and methods of use thereof (2019-11-12),

14. 10287303 - Compositions and methods for inhibiting arginase activity (2019-05-14),

15. 10065974 - Compositions and methods for inhibiting arginase activity (2018-09-04),

Title: Jim W. Li: Innovator in Ectonucleotidase Inhibitors

Introduction

Jim W. Li is an accomplished inventor based in San Jose, CA, recognized for his significant contributions to the field of pharmaceuticals. With a total of 35 patents to his name, Jim has made remarkable strides in developing innovative compounds aimed at treating severe diseases, particularly cancer.

Latest Patents

Among his latest achievements, Jim has patented an invention titled "Ectonucleotidase inhibitors and methods of use thereof," which relates to novel heterocyclic compounds demonstrating CD73 inhibitory activity. These compounds and their pharmaceutical preparations hold promise for the treatment and prevention of cancer. Another interesting patent he holds under the same title highlights additional heterocyclic compounds with similar therapeutic applications, reinforcing his commitment to advancing cancer treatment through innovative science.

Career Highlights

Throughout his career, Jim has worked with esteemed companies such as Calithera Biosciences, Inc. and Roche Palo Alto LLC. His positions within these organizations provided him with the platform to explore and develop his groundbreaking innovations in biotechnology and pharmaceuticals.

Collaborations

Jim’s work has also involved collaboration with notable peers, including Eric Brian Sjogren and Lijing Chen. These collaborations represent a fusion of talents and ideas that contribute to the success of his research and inventions, fostering an innovative environment that promotes the development of new therapies.

Conclusion

Jim W. Li stands out not only for his impressive patent portfolio but also for his unwavering dedication to the advancement of medical science. His work in ectonucleotidase inhibitors and collaborations with fellow inventors highlight the power of innovation in addressing complex health challenges. As he continues to develop new compounds, Jim's contributions are poised to make a lasting impact on cancer treatment and patient care.